Myostatin and activin A are the two primary negative regulators of muscle mass. Blocking these circulating ligands during GLP-1 therapy induces improved body composition through preservation of lean mass and enhanced fat mass loss in obese primates.
- Jason W. Mastaitis
- Daniel Gomez
- Mark W. Sleeman
